167 related articles for article (PubMed ID: 18543017)
1. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
3. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
4. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.
Sun L; Su XH; Guan YS; Pan WM; Luo ZM; Wei JH; Wu H
World J Gastroenterol; 2008 Aug; 14(29):4627-32. PubMed ID: 18698676
[TBL] [Abstract][Full Text] [Related]
6. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
7. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A
Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102
[TBL] [Abstract][Full Text] [Related]
8. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
9. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
11. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
13. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
14. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.
Lee JW; Lee SM; Son MW; Lee MS
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):881-888. PubMed ID: 26611426
[TBL] [Abstract][Full Text] [Related]
16. Value of ¹⁸F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension.
Ma Q; Xin J; Zhao Z; Guo Q; Yu S; Xu W; Liu C; Zhai W
Eur J Radiol; 2013 Jun; 82(6):e302-6. PubMed ID: 23434453
[TBL] [Abstract][Full Text] [Related]
17. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study.
Nakamoto Y; Togashi K; Kaneta T; Fukuda H; Nakajima K; Kitajima K; Murakami K; Fujii H; Satake M; Tateishi U; Kubota K; Senda M
Jpn J Clin Oncol; 2009 May; 39(5):297-302. PubMed ID: 19269991
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]